Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more
Bristol-Myers Squibb shares have moved in a contained range over the past month, closing near $61 in late October 2026 after trading between roughly $56 and $64 over the preceding several weeks. The roughly 2% pullback over the trailing 30 days stands in contrast to the stock's stronger year-to-date advance of about 14%, indicating that momentum has cooled as investors weigh pipeline execution against patent-related headwinds.
Analyst sentiment remains moderately positive, with a consensus "Moderate Buy" rating and an average price target near $66, though individual estimates vary widely. The stock also offers a dividend yield around 4%, which has historically attracted income-oriented investors during periods of price consolidation.
Bristol-Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and commercializing medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience. Its best-known products include the blood thinner Eliquis, developed in collaboration with Pfizer, and the immuno-oncology therapy Opdivo.
The company is executing a portfolio transformation. While legacy blockbusters such as Revlimid and Pomalyst face generic competition, a newer "growth portfolio" spanning Reblozyl, Breyanzi, Camzyos, Opdualag, Sotyktu and the schizophrenia treatment Cobenfy is expanding rapidly and now represents close to 60% of total sales. This shift toward products with longer growth runways is central to the investment thesis, as it positions the company to offset declining legacy revenue while funding a pipeline that includes cell therapy and next-generation immunology assets.
Second-quarter 2026 results, reported in late July, beat consensus expectations, with adjusted earnings per share of $2.04 on revenue of roughly $12.97 billion. Management raised full-year 2026 revenue guidance to approximately $49–$50 billion and non-GAAP EPS guidance to $6.75–$7.00, citing Eliquis strength and momentum across growth products.
Pipeline news has also influenced sentiment. In mid-October, the company reported positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis and for RYZ101 in neuroendocrine tumors. However, a late-October disclosure of a patient death in an early-stage CAR-T study for multiple sclerosis triggered a decline of about 2% in the stock, underscoring the safety risks that accompany the cell therapy class.
On the strategic front, Bristol-Myers Squibb has deepened its use of artificial intelligence through collaborations with Pathos AI and Tempus AI, as well as partnerships with NVIDIA and Anthropic, aimed at improving drug discovery and trial design.
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe of automated strategies. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant bots appear in this featured section. The bots differ in approach, timeframe and performance metrics, ranging from short-term swing strategies to longer-horizon models. For investors seeking a data-driven complement to fundamental research, exploring the section can offer a view into how automated systems are positioning across the market.
The next major catalyst is Bristol-Myers Squibb's third-quarter 2026 earnings report, expected in late October, which will test the durability of growth portfolio momentum and provide an update on full-year guidance. Beyond earnings, investors are watching pivotal clinical readouts, including the milvexian studies in stroke prevention and atrial fibrillation now expected in early 2027, as well as additional data on admilparant.
The gradual ramp of Cobenfy and the potential launches of the CELMoD candidates iberdomide and mezigdomide represent important long-term drivers. At the same time, the 2028 loss of exclusivity on Eliquis remains a key risk, alongside ongoing safety scrutiny of CAR-T therapies and broader regulatory and pricing pressures across the pharmaceutical sector. These factors will likely shape both the company's fundamentals and investor sentiment in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BMY's Aroon Indicator triggered a bullish signal on November 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In 150 of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 69%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Oscillator exited the oversold zone, 10 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 33%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 175 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 52 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 28 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
BMY moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor